Shares will move to the OTC or cease trading entirely as the company goes dark. Given only 5 holders of record, this is a definitive end to public market participation, any remaining CNTA equity is essentially illiquid. Traders should close any positions immediately; there is no future catalyst path that restores public reporting.
Price Chart
Executive Summary
Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its ordinary shares and American Depositary Shares under Section 12(g) of the Exchange Act, terminating its SEC reporting obligations. The filing follows a Nasdaq delisting notice (Form 25-NSE) filed June 24, 2026, confirming a complete exit from public markets with only 5 holders of record. This represents a terminal liquidity event for remaining shareholders who will lose all public company transparency and most secondary trading access.
Key Facts
- Centessa Pharmaceuticals filed Form 15-12G to terminate registration under Section 12(g) of the Securities Exchange Act of 1934
- Deregistration covers both Ordinary Shares and American Depositary Shares (ADSs)
- Approximate number of holders of record as of certification date: 5
- Filed concurrently with a Form 25-NSE (delisting notice) from June 24, 2026, confirming the securities were already being removed from Nasdaq
- No securities remain registered; no other classes have a duty to file reports under Section 13(a) or 15(d)
Financial Impact
Complete loss of SEC reporting transparency; no public market liquidity for remaining shares; no financial figures disclosed in filing
Risk Factors
- Complete loss of SEC financial reporting creates information asymmetry for remaining shareholders
- Illiquidity, no exchange listing means wide bid-ask spreads or no secondary market at all
- Potential for zero return on remaining equity if no going-private transaction accompanies the deregistration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001193125-26-295685 |
| Document: 0001193125-26-295685-index-headers.html | 0001193125-26-295685 |
| Document: 0001193125-26-295685-index.html | 0001193125-26-295685 |
| Document: 0001193125-26-295685.txt | 0001193125-26-295685 |
Track record
5 reports on CNTA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 4 of 4 went positive at some point.
Filters
- Jul 6, 202619w ago 15-12G Bearish 7/10 Viewing No price data
- Apr 17, 202630w ago PREM14A Bullish 9/10 Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
- Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 7/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 6/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers